Quanterix Corporation, a Tufts University spinout, has raised $15 million in Series A financing to develop and validate a variety of ultrasensitive diagnostic and drug-discovery assays based on single-molecule detection technology, the company said last week.
The core technology was developed by Tufts University chemistry professor David Walt, who has a history of entrepreneurial activity including co-founding genetic-analysis company Illumina, in which Tufts took an equity stake when it was founded in 1998.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Oxford Nanopore Technologies is looking into dual listings in London and Hong Kong, according to the South China Morning Post.

The New York Times looks into medical research funding in the US and how the grant system might not be funding the best work.

US lawmakers proposed increasing the National Science Foundation budget, including its facilities account, Science reports.

In PNAS this week: effects of gene deletions on bacterial metabolic networks, genetic responses to sea star wasting disease, and more.